Given that without a halogen or pseudohalogen activity is either absent or nearly so, whatever activity 7-amino-clonazepam has will be irrelevant, as the EC50 will never be reached, so there will be no activity.
If there's any active dose for 7-amino-clonazepam, you're pretty sure to be looking in the 100's to 1000's of mg's.
edit: 30 seconds of searching says I'm right:
Residual effect of a 7-amino metabolite of clonazepam on GABAA receptor function in the nucleus reticularis thalami of the rat
Mitsutoshi Munakata and Shigeru Tsuchiya
Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan
Address correspondence to Mitsutoshi Munakata, M.D., Ph.D., Department of Pediatrics, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. E-mail:
[email protected]
Copyright Copyright © 2008 by the International League Against Epilepsy
KEYWORDS
7-aminoclonazepam • Clonazepam • GABAA receptor • Benzodiazepine re-ceptor • Nucleus reticularis thalami • Withdrawal symptoms
ABSTRACT
A considerable amount of 7-aminoclonazepam (ACZP), a major metabolite of clonazepam (CZP), is present in the brain during CZP treatment, yet the pharmacological properties of ACZP remain unknown. We investigated the effects of ACZP on the GABAA receptor-mediated currents (IGABA) in neurons from the nucleus reticularis thalami (NRT) of the rat, using a nystatin-perforated patch technique. Neurons in which CZP (10 nM) exerted prominent augmentation (>100% augmentation) of IGABA, which comprised 32% of the neurons tested, were included for the analysis of ACZP. In these neurons, ACZP augmented IGABA, which was blocked by 10 μM flumazenil, a benzodiazepine receptor (BZR) antagonist. The half-maximal effective concentration of ACZP was 124 nM, whereas that of CZP was 1.8 nM. The maximal enhancements induced by ACZP and CZP were 38% and 170%, respectively. In neurons from the ventrobasal complex of the thalamus, the effect of ACZP was negligible. Our results suggest that ACZP was a weak partial BZR agonist and that ACZP may competitively modify the effect of CZP, leading to clinical consequences for patients with high levels of ACZP.
http://www3.interscience.wiley.com/journal/120120311/abstract?CRETRY=1&SRETRY=0